Jonni Moore
University of Pennsylvania
Jonni Moore, Ph.D. is Professor of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Scientific Director of the Penn Cytomics and Cell Sorting Shared Resource and Emeritus Director, Founder and currently Senior Advisor of the Clinical Flow Cytometry Laboratory of the Hospital of the University of Pennsylvania. She is the immediate Past President of the International Society for the Advancement of Cytometry (2020-2022) and the 2018 winner of the ISAC Member Award for Distinguished and Transformational Contributions to the field of flow cytometry.
Dr. Moore has more than 30 years of experience in laboratory medicine, cellular immunology and cytomics. One of the world’s leading experts in flow cytometry, she is looked to as a thought leader in cutting-edge applications of deep phenotyping flow cytometry in translational and clinical settings, as evidenced by recent accolades from the National Cancer Institute citing her as “an absolutely stellar scientific director and an internationally recognized authority”. She has over 100 peer-reviewed publications and is a frequent invited speaker at national and international meetings. She holds several patents for unique applications of flow cytometry in cardiology, toxicology and oncology. In 2016, she received the Wallace H. Coulter Distinguished Lecturer Award for lifetime contributions to the science, education and practice of Clinical Cytometry.
Dr. Moore received her Ph.D. in Microbiology and Immunology from Thomas Jefferson University in Philadelphia and did a post-doc with Peter Nowell, MD in the Immunology Graduate Group at the University of Pennsylvania. She has served as Director of the Abramson Cancer Center Flow Cytometry and Cell Sorting Shared Resource (now Penn Cytomics and Cell Sorting Resource Laboratory) since 1991, a facility that has consistently been recognized as one of the largest and most comprehensive academic flow cytometry resource laboratories in the US, winning the designation of exceptional from the National Cancer Institute of the NIH for 6 consecutive cycles. She was appointed the first director of the Clinical Flow Cytometry Laboratory at the Hospital of the University of Pennsylvania, and combines her clinical and research expertise in directing the newly established Translational Cytomics laboratory where she and colleagues use high parameter single cell analysis to address clinical issues. Their approach is comprehensive as they also develop and implement unique computational algorithms to process this high parameter multiomic data.
Building on her experiences in both basic and translational research, she has led the effort at Penn to bring technologies from the newly developing field of cytomics to investigators in diverse disciplines across the campus. Being in the unique position of leadership in both clinical and research flow cytometry, she has focused on movement of novel translational assays to the clinical lab, developing new flow cytometric tests in the areas of toxicology, oncology, hematology and cardiology. She served as a co-founder of CytoVas LLC, a University of Pennsylvania innovation start-up focused unique cardiovascular cytometric diagnostics, creating the first-in-sector clinical flow cytometry test for cardiovascular disease. Over the years she has served as a consultant for several biotech, biopharma and venture groups on the role of cytometry in discovery, development and ultimately in patient care. Her particular interest is in bringing cutting-edge technologies to the clinic and integrating multiomic approaches in diagnostics, prognostics and theranostics.
